FTC resolves Express Scripts case with ‘landmark settlement’

The pharmacy benefits manager has copped to artificially inflating the list price of drugs by using unfair rebating practices.

The Federal Trade Commission (FTC) has announced a “landmark settlement” with Cigna Group’s Express Scripts, Inc., and its affiliated entities (collectively “ESI”), one of the nation’s largest pharmacy benefit managers.

The settlement requires ESI to adopt “fundamental changes” to its business practices that increase transparency and bring millions of dollars

Register for free to keep reading

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day